The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Adversarial Threshold Neural Computer for Molecular de Novo Design
Open accessAbstract
In this article, we propose the deep neural network Adversarial Threshold Neural Computer (ATNC). The ATNC model is intended for the de novo design of novel small-molecule organic structures. The model is based on generative adversarial network architecture and reinforcement learning. ATNC uses a Differentiable Neural Computer as a generator and has a new specific block, called adversarial threshold (AT). AT acts as a filter between the agent (generator) and the environment (discriminator + objective reward functions). Furthermore, to generate more diverse molecules we introduce a new objective reward function named Internal Diversity Clustering (IDC). In this work, ATNC is tested and compared with the ORGANIC model. Both models were trained on the SMILES string representation of the molecules, using four objective functions (internal similarity, Muegge druglikeness filter, presence or absence of sp3-rich fragments, and IDC). The SMILES representations of 15K druglike molecules from the ChemDiv collection were used as a training data set. For the different functions, ATNC outperforms ORGANIC. Combined with the IDC, ATNC generates 72% of valid and 77% of unique SMILES strings, while ORGANIC generates only 7% of valid and 86% of unique SMILES strings. For each set of molecules generated by ATNC and ORGANIC, we analyzed distributions of four molecular descriptors (number of atoms, molecular weight, logP, and tpsa) and calculated five chemical statistical features (internal diversity, number of unique heterocycles, number of clusters, number of singletons, and number of compounds that have not been passed through medicinal chemistry filters). Analysis of key molecular descriptors and chemical statistical features demonstrated that the molecules generated by ATNC elicited better druglikeness properties. We also performed in vitro validation of the molecules generated by ATNC; results indicated that ATNC is an effective method for producing hit compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hochreiter, S., & Schmidhuber, J. (1997) · Neural Computation · doi:10.1162/neco.1997.9.8.1735 · Cited by 102,318
LeCun, Y., Bengio, Y., & Hinton, G. (2015) · Nature · doi:10.1038/nature14539 · Cited by 84,126
Reinforcement Learning: An Introduction
Sutton, R. S., & Barto, A. G. (1998) · IEEE Transactions on Neural Networks · doi:10.1109/tnn.1998.712192 · Cited by 27,225
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
Weininger, D. (1988) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci00057a005 · Cited by 7,436
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
Automatic Chemical Design Using a Data-Driven Continuous Representation of Molecules
Gómez-Bombarelli, R., Wei, J. N., Duvenaud, D., Hernández-Lobato, J. M., Sánchez-Lengeling, B., Sheberla, D., Aguilera-Iparraguirre, J., Hirzel, T. D., Adams, R. P., & Aspuru-Guzik, A. (2018) · ACS Central Science · doi:10.1021/acscentsci.7b00572 · Cited by 3,106
Principles of early drug discovery
Hughes, J., Rees, S., Kalindjian, S., & Philpott, K. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01127.x · Cited by 2,859
Cited by
Deep learning enables rapid identification of potent DDR1 kinase inhibitors
Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., Veselov, M. S., Aladinskiy, V. A., Aladinskaya, A. V., Terentiev, V. A., Polykovskiy, D. A., Kuznetsov, M. D., Asadulaev, A., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0224-x · Cited by 1,573
Self-citationConcepts of Artificial Intelligence for Computer-Assisted Drug Discovery
Yang, X., Wang, Y., Byrne, R., Schneider, G., & Yang, S. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00728 · Cited by 1,022
GuacaMol: Benchmarking Models for de Novo Molecular Design
Brown, N., Fiscato, M., Segler, M. H. S., & Vaucher, A. C. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00839 · Cited by 895
Molecular Sets (MOSES): A Benchmarking Platform for Molecular Generation Models
Polykovskiy, D., Zhebrak, A., Sanchez-Lengeling, B., Golovanov, S., Tatanov, O., Belyaev, S., Kurbanov, R., Artamonov, A., Aladinskiy, V., Veselov, M., et al. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.565644 · Cited by 849
“Much of the popularity behind SMILES in molecular generative models [40–48] has been due to the fast adaptation of sequence modeling tools such as recurrent neural networks, attention mechanisms, and dilated convolutions, among others, to the text nature of SMILES.”
BackgroundSelf-citationDeep learning for molecular design—a review of the state of the art
Elton, D. C., Boukouvalas, Z., Fuge, M. D., & Chung, P. W. (2019) · Molecular Systems Design & Engineering · doi:10.1039/c9me00039a · Cited by 683
Exploiting machine learning for end-to-end drug discovery and development
Ekins, S., Puhl, A. C., Zorn, K. M., Lane, T. R., Russo, D. P., Klein, J. J., Hickey, A. J., & Clark, A. M. (2019) · Nature Materials · doi:10.1038/s41563-019-0338-z · Cited by 578
MolGPT: Molecular Generation Using a Transformer-Decoder Model
Bagal, V., Aggarwal, R., Vinod, P. K., & Priyakumar, U. D. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00600 · Cited by 543
A de novo molecular generation method using latent vector based generative adversarial network
Prykhodko, O., Johansson, S. V., Kotsias, P.-C., Arús-Pous, J., Bjerrum, E. J., Engkvist, O., & Chen, H. (2019) · Journal of Cheminformatics · doi:10.1186/s13321-019-0397-9 · Cited by 402
Optimization of Molecules via Deep Reinforcement Learning
Zhou, Z., Kearnes, S., Li, L., Zare, R. N., & Riley, P. (2019) · Scientific Reports · doi:10.1038/s41598-019-47148-x · Cited by 401
Aging Biomarker Consortium, Bao, H., Cao, J., Chen, M., Chen, M., Chen, W., Chen, X., Chen, Y., Chen, Y., Chen, Y., et al. (2023) · Science China Life Sciences · doi:10.1007/s11427-023-2305-0 · Cited by 376
Ren, F., Ding, X., Zheng, M., Korzinkin, M., Cai, X., Zhu, W., Mantsyzov, A., Aliper, A., Aladinskiy, V., Cao, Z., et al. (2023) · Chemical Science · doi:10.1039/d2sc05709c · Cited by 365
Self-citationAdvances in De Novo Drug Design: From Conventional to Machine Learning Methods
Mouchlis, V. D., Afantitis, A., Serra, A., Fratello, M., Papadiamantis, A. G., Aidinis, V., Lynch, I., Greco, D., & Melagraki, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041676 · Cited by 353
Constrained Bayesian optimization for automatic chemical design using variational autoencoders
Griffiths, R.-R., & Hernández-Lobato, J. M. (2020) · Chemical Science · doi:10.1039/c9sc04026a · Cited by 339
Autonomous Discovery in the Chemical Sciences Part I: Progress
Coley, C. W., Eyke, N. S., & Jensen, K. F. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201909987 · Cited by 317
Generative Models as an Emerging Paradigm in the Chemical Sciences
Anstine, D. M., & Isayev, O. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c13467 · Cited by 313
Entangled Conditional Adversarial Autoencoder for de Novo Drug Discovery
Polykovskiy, D., Zhebrak, A., Vetrov, D., Ivanenkov, Y., Aladinskiy, V., Mamoshina, P., Bozdaganyan, M., Aliper, A., Zhavoronkov, A., & Kadurin, A. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00839 · Cited by 278
Self-citationAssessing the impact of generative AI on medicinal chemistry
Walters, W. P., & Murcko, M. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0418-2 · Cited by 262
Efficient multi-objective molecular optimization in a continuous latent space
Winter, R., Montanari, F., Steffen, A., Briem, H., Noé, F., & Clevert, D.-A. (2019) · Chemical Science · doi:10.1039/c9sc01928f · Cited by 260
The transformational role of GPU computing and deep learning in drug discovery
Pandey, M., Fernandez, M., Gentile, F., Isayev, O., Tropsha, A., Stern, A. C., & Cherkasov, A. (2022) · Nature Machine Intelligence · doi:10.1038/s42256-022-00463-x · Cited by 255
Artificial intelligence for aging and longevity research: Recent advances and perspectives
Zhavoronkov, A., Mamoshina, P., Vanhaelen, Q., Scheibye-Knudsen, M., Moskalev, A., & Aliper, A. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2018.11.003 · Cited by 246
Accelerating antibiotic discovery through artificial intelligence
Melo, M. C. R., Maasch, J. R. M. A., & de la Fuente-Nunez, C. (2021) · Communications Biology · doi:10.1038/s42003-021-02586-0 · Cited by 234
Unleashing the power of generative AI in drug discovery
Gangwal, A., & Lavecchia, A. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.103992 · Cited by 195
Generative machine learning for de novo drug discovery: A systematic review
Martinelli, D. D. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105403 · Cited by 177
Will Artificial Intelligence for Drug Discovery Impact Clinical Pharmacology?
Zhavoronkov, A., Vanhaelen, Q., & Oprea, T. I. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1795 · Cited by 159
Self-citationThe Advent of Generative Chemistry
Vanhaelen, Q., Lin, Y.-C., & Zhavoronkov, A. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00088 · Cited by 151
Self-citationQuantum computing for near-term applications in generative chemistry and drug discovery.
Pyrkov, A., Aliper, A., Bezrukov, D., Lin, Y.-C., Polykovskiy, D., Kamya, P., Ren, F., & Zhavoronkov, A. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103675 · Cited by 100
Self-citationVerkhivker, G. M., Agajanian, S., Hu, G., & Tao, P. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00136 · Cited by 76
Retro Drug Design: From Target Properties to Molecular Structures
Wang, Y., Michael, S., Yang, S.-M., Huang, R., Cruz-Gutierrez, K., Zhang, Y., Zhao, J., Xia, M., Shinn, P., & Sun, H. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00123 · Cited by 24
Metadata
- Authors
- Putin, E., Asadulaev, A., Vanhaelen, Q., Ivanenkov, Y., Aladinskaya, A. V., Aliper, A., & Zhavoronkov, A.
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-03-23
- Volume
- 15
- Issue
- 10
- Pages
- 4386-4397
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W2793945656
- Cited by
- 211
- References
- 17
- FWCI
- 17.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.